高流量鼻导管氧疗与无创通气治疗急性心源性肺水肿的比较:一项随机对照先导研究
这项多中心随机先导研究在法国三个急诊科纳入60例疑似急性心衰所致急性呼吸衰竭的成人患者,随机接受高流量氧疗(最低50 l/min)或无创双水平正压通气。主要终点为治疗1小时内呼吸频率变化,高流量氧疗组中位变化-10次/分,无创通气组-7次/分,估计差异-2.6次/分(95%CI -0.5至5.7),P=0.052,未达统计学显著。SpO2变化、PaO2、PaCO2、pH、治疗失败、插管及死亡率在两组间均无差异。作者认为点估计及宽置信区间可能提示高流量氧疗获益。
要点
- 急性心衰相关急性呼吸衰竭成人患者中,高流量氧疗(最低50 l/min)与无创双水平正压通气1小时内呼吸频率中位变化分别为-10次/分与-7次/分,估计差异-2.6次/分(95%CI -0.5至5.7),P=0.052
- 高流量氧疗组与无创通气组1小时SpO2中位变化均为2%,估计差异0.8%(95%CI -1.1至2.8),P=0.60
- 两组1小时PaO2、PaCO2、pH及治疗失败、插管、死亡率均无差异
- 作者认为点估计及宽置信区间可能提示高流量氧疗获益,但本研究为先导研究,未观察到统计学显著差异
- 纳入标准为疑似急性心衰所致急性呼吸衰竭成人;关键排除标准包括急需插管、格拉斯哥昏迷评分<13分或血流动力学不稳定
适用人群与场景
- 法国三个急诊科收治的疑似急性心衰所致急性呼吸衰竭成人患者
- 关键排除标准:急需插管、格拉斯哥昏迷评分<13分或血流动力学不稳定
处置流程与药物剂量
- 高流量氧疗组:经高流量鼻导管给氧,最低50 l/min
- 无创通气组:无创双水平正压通气
红旗征与不能漏的情况
- 急需插管者排除
- 格拉斯哥昏迷评分<13分者排除
- 血流动力学不稳定者排除
研究设计与关键结果
- 多中心随机先导研究,法国三个急诊科,145例符合条件患者中60例纳入分析,中位年龄86岁(IQR 90;92)
- 高流量氧疗组与无创通气组基线呼吸频率中位数分别为30.5次/分(IQR 28;33)与29.5次/分(IQR 27;35)
- 主要终点:1小时呼吸频率中位变化高流量氧疗组-10次/分(IQR -12;-8)vs 无创通气组-7次/分(IQR -11;-5),估计差异-2.6次/分(95%CI -0.5至5.7),P=0.052
- 1小时SpO2中位变化高流量氧疗组2%(IQR 0;5)vs 无创通气组2%(IQR -1;5),估计差异0.8%(95%CI -1.1至2.8),P=0.60
- 1小时PaO2、PaCO2、pH两组间无差异
- 治疗失败、插管及死亡率两组间无差异
证据类型、等级与局限
- 证据类型:多中心随机对照先导研究
- 局限:原文未报告局限性
对床旁实践的改变
- 对于疑似急性心衰所致急性呼吸衰竭的成人患者,高流量氧疗(最低50 l/min)与无创双水平正压通气在1小时内呼吸频率改善方面未观察到统计学显著差异,但点估计及宽置信区间可能提示高流量氧疗获益(作者认为)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether high-flow nasal oxygen can improve clinical signs of acute respiratory failure in acute heart failure (AHF) is uncertain.
OBJECTIVE: To compare the effect of high-flow oxygen with noninvasive ventilation (NIV) on respiratory rate in patients admitted to an emergency department (ED) for AHF-related acute respiratory failure.
DESIGN, SETTINGS AND PARTICIPANTS: Multicenter, randomized pilot study in three French EDs. Adult patients with acute respiratory failure due to suspected AHF were included. Key exclusion criteria were urgent need for intubation, Glasgow Coma Scale <13 points or hemodynamic instability.
INTERVENTION: Patients were randomly assigned to receive high-flow oxygen (minimum 50 l/min) or noninvasive bilevel positive pressure ventilation.
OUTCOMES MEASURE: The primary outcome was change in respiratory rate within the first hour of treatment and was analyzed with a linear mixed model. Secondary outcomes included changes in pulse oximetry, heart rate, blood pressure, blood gas samples, comfort, treatment failure and mortality.
MAIN RESULTS: Among the 145 eligible patients in the three participating centers, 60 patients were included in the analysis [median age 86 (interquartile range (IQR), 90; 92) years]. There was a median respiratory rate of 30.5 (IQR, 28; 33) and 29.5 (IQR, 27; 35) breaths/min in the high-flow oxygen and NIV groups respectively, with a median change of -10 (IQR, -12; -8) with high-flow nasal oxygen and -7 (IQR, -11; -5) breaths/min with NIV [estimated difference -2.6 breaths/min (95% confidence interval (CI), -0.5-5.7), P = 0.052] at 60 min. There was a median SpO 2 of 95 (IQR, 92; 97) and 96 (IQR, 93; 97) in the high-flow oxygen and NIV groups respectively, with a median change at 60 min of 2 (IQR, 0; 5) with high-flow nasal oxygen and 2 (IQR, -1; 5) % with NIV [estimated difference 0.8% (95% CI, -1.1-2.8), P = 0.60]. PaO 2 , PaCO 2 and pH did not differ at 1 h between groups, nor did treatment failure, intubation and mortality rates.
CONCLUSION: In this pilot study, we did not observe a statistically significant difference in changes in respiratory rate among patients with acute respiratory failure due to AHF and managed with high-flow oxygen or NIV. However, the point estimate and its large confidence interval may suggest a benefit of high-flow oxygen.
TRIAL REGISTRATION: NCT04971213 ( https://clinicaltrials.gov ).
参考来源
- Marjanovic N, Piton M, Lamarre J, et al. High-flow nasal cannula oxygen versus noninvasive ventilation for the management of acute cardiogenic pulmonary edema: a randomized controlled pilot study. Eur J Emerg Med. 2024. PMID: 38364020. doi:10.1097/MEJ.0000000000001128
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。